-
Mashup Score: 0Mohty Shares Key Takeaway From the 50th Annual EMBT Meeting, Highlighting Treatment of GVHD - 13 hour(s) ago
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8New Evidence Explains Why Some Targeted Therapies Support Better Response to Cancer Immunotherapy - 14 hour(s) ago
A Roswell Park-led team uncovers beneficial effects of combining VEGFR-targeting TKIs with checkpoint inhibitors in new research.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Revisit Every OncLive On Air Episode From April 2024 - 15 hour(s) ago
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Melanoma is often detected later in people with darker skin complexions and the consequences can be devastating, a Mayo Clinic study reveals.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Real-World Study Sheds Light on Treatment Sequences and Second-Line Outcomes in HER2+ Breast Cancer - 16 hour(s) ago
A real-world study dives into treatment sequencing data and indicates most patients with HER2-positive metastatic breast cancer discontinued second-line treatment in the US.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Mohamad Mohty, MD, PhD, discusses unmet needs for patients with chronic or acute GVHD, for whom standard-of-care therapies often fall short.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC - 18 hour(s) ago
Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC - 19 hour(s) ago
Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC - 20 hour(s) ago
Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC - 23 hour(s) ago
A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Mohty Shares Key Takeaway From the 50th Annual EMBT Meeting, Highlighting Treatment of GVHD @mohty_ebmt @hopsaintantoine @Sorbonne_Univ_ @theebmt #oncology #EBMT24 https://t.co/tcLAydy03t